Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Other stocks to invest in
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(510)
•••
Comment by YukonJezzaon May 27, 2021 1:14am
138 Views
Post# 33273689

RE:RE:Other stocks to invest in

RE:RE:Other stocks to invest in
MrMugsy wrote:
CandyC wrote:

I trimmed a lot of my Antibe today. Better stocks to invest in such as oil. Large in Gear and Athabasca  Eric is on Market Call Friday  should be a big boost for these penny stocks  

https://www.bnnbloomberg.ca/eric-nuttall-s-top-picks-april-30-2021-1.1597554



Funny!  I hit a record high in my ATE share count today.
Taking shares from weak hands at around $3.90.
Keep the shares a coming my way !!!!


I, on the other hand will not lie to you. I added zilch at 3.90 because it's only May. We have Have till September to drop. I should have pulled this three weeks ago and bought DDD printing .
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities